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Abstract
Background: We have previously shown that ADP-induced TXA2 generation requires signaling from aIIbb3 integrin in
platelets. Here we observed that, unlike ADP, protease-activated receptor (PAR)-mediated TXA2 generation occurs
independently of aIIbb3. PAR agonists, but not ADP, activate G12/13 signaling pathways. Hence, we evaluated the role of
these pathways in TXA2 generation.
Principal Findings: Inhibition of ADP-induced thromboxane generation by fibrinogen receptor antagonist SC57101 was
rescued by co-stimulation of G12/13 pathways with YFLLRNP. This observation suggested an existence of a common
signaling effector downstream of integrins and G12/13 pathways. Hence, we evaluated role of three potential tyrosine
kinases; c-Src, Syk and FAK (Focal Adhesion Kinase) that are known to be activated by integrins. c-Src and Syk kinase did not
play a role in ADP-induced functional responses in platelets. Selective activation of G12/13 pathways resulted in the
activation of FAK, in the absence of integrin signaling. Interestingly, aIIbb3-mediated FAK activation occurred in a Src family
kinase (SFK)-independent manner whereas G12/13 pathway caused FAK activation in a SFK and RhoA-dependent manner. A
FAK selective inhibitor TAE-226, blocked TXA2 generation. However, in comparison to WT mice, Pf4-Cre/Fak-Floxed mice did
not show any difference in platelet TXA2 generation.
Conclusions: Therefore, we conclude that differential activation of FAK occurs downstream of Integrins and G12/13
pathways. However, the common effector molecule, possibly a tyrosine kinase downstream of integrins and G12/13
pathways contributing to TXA2 generation in platelets remains elusive.
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Introduction
Platelet activation is an essential component of hemostasis and
thrombosis, and involves engagement of complex signaling
machinery. Injury to sub-endothelium results in platelet adhesion,
and subsequent spreading on exposed collagen. Platelet activation
also leads to reorganization of platelet cytoskeleton, release of
granular contents from dense and alpha granules and finally
culminates in integrin activation leading to platelet aggregation
[1,2,3]. ADP released from the dense granules and the
thromboxaneA2 (TXA2) generated from activated platelets further
act as positive feedback mediators and amplify the initial platelet
responses and stabilize the hemostatic plug [4,5].
TXA2 is generated from its precursor arachidonic acid through
cycloxygenase pathway [6]. TXA2 acts on the TP (Prostanoid)
receptors and recruits more platelets to the site of injury. Platelets
can be activated by broad range of agonists, which can be further
classified as strong or weak. ADP, serotonin, and epinephrine, are
considered weak agonists [7] whereas thrombin, SFLLRNP (PAR1
agonist), AYPGKF (PAR4 agonist) [8], and Convulxin (GP VI
agonist) [9] are strong agonists. Not only these agonists activate
platelets with varied potencies but they also induce distinct signaling
pathways. Previous studies have shown that ADP-induced TXA2
generation in platelets is integrin-dependent [10] however; it is not
known whether stronger agonists such as thrombin depend on
integrin-mediated signaling for TXA2 generation.
ADP activates two G-protein coupled receptors P2Y1 and
P2Y12, activating Gq and Gi pathways, respectively [1,3]. In
platelets, neither of the ADP receptors can couple to G12/13
proteins whereas PAR receptors couple to G12/13 proteins [11].
G12/13 pathways have been shown to activate Rho kinase [12] and
Src family kinases (SFKs) [13]. Earlier studies have shown that
G12/13 pathways mediate calcium-independent shape change
[12,14], and play a potentiating role in Akt phosphorylation
[13] and dense granule secretion [15]. Co-stimulation of platelets
with G12/13 and Gi also leads to platelet aggregation [16].
Agonist binding to platelet receptors results in complex
intracellular signaling events termed as inside-out signaling, which
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integrins change conformation and bind multivalent ligands
such as fibrinogen and von Wilebrand Factor (vWF) [17].
Signaling events from ligand binding to fibrinogen receptor are
termed as outside-in signaling wh i c h ,i nt u r nr e g u l a t ep l a t e l e t
adhesion, spreading, and clot retraction [18]. Outside-in
signaling also causes phosphorylation of b3 cytoplasmic tails
[19,20], and activation of Phospholipase C (PLC c)[ 2 1 ] ,
tyrosine kinases such as c-Src, Syk [21] and Focal adhesion
kinase (FAK) [22]. FAK is a 125 kDa protein, expressed in both
megakaryocytes and platelets [23]. FAK is tyrosine phosphor-
ylated on six tyrosine residues viz., Y397, Y407, Y576/577,
Y861 and Y925 [24].
Other signaling molecules, involved in outside-in signaling are
Protein Tyrosine Phosphatase-1B (PTP-1B) [25], Protein Phos-
phatase 1C (PP1c) [26], Calcium and integrin binding protein
(CIB) [27] and Protein Kinase C-b (PKC-b) [28,29].
In this study we show that, G12/13 pathways, cause TXA2
generation even when signaling from integrin is blocked. We
present an evidence that c-Src and Syk kinase do not play a role in
ADP-induced functional responses and FAK can be activated
downstream of integrin aIIbb3 as well as G12/13 pathways.
However, G12/13-mediated activation of FAK occurs via Rho
kinase and SFKs, whereas integrin-mediated FAK activation is
independent of SFKs. Studies to evaluate the role of FAK in
thromboxane generation showed that FAK does not contribute to
thromboxane generation downstream of integrins. In conclusion,
neither c-Src, Syk nor FAK contribute to integrin-mediated
thromboxane generation in platelets. Therefore, the common
signaling molecule downstream of integrins and G12/13 remains
yet to be identified.
Results
Regulation of thromboxane generation in platelets by
G12/13 pathways
ADP-induced TXA2 generation is dependent on integrin
activation and as pre-treatment of platelets with fibrinogen
receptor antagonist (SC57101) abrogated ADP-induced TXA2
generation [10]. We investigated the effect of a fibrinogen receptor
antagonist (SC57101) on PAR-mediated TXA2 generation. Searle
Research developed SC57101 (Skokie, IL) based on the RGDS
structure. SC57101 and its analogs are fibrinogen receptor
antagonists and do not affect inside out signaling [10]. As shown
in Fig. 1A, varying concentrations of AYPGKF, a PAR4 agonist,
caused TXA2 generation in the presence or absence of SC57101,
indicating that PAR agonists cause thromboxane generation
independently of integrin signaling. One of the main signaling
differences between ADP and PAR agonists is that only PAR
agonists can activate G12/13 pathways [11]. In order to evaluate
the role of G12/13 pathways in platelet TXA2 generation we co-
stimulated platelets with 2MeSADP and/or YFLLRNP. 2Me-
SADP is a more potent agonist than ADP at the P2Y1 and P2Y12
receptors [30] and YFLLRNP is a weak agonist of PAR1 that
selectively activates G12/13 pathways (at low doses) [16,31]. As
shown in Fig. 1B, 2MeSADP-induced thromboxane generation
was completely blocked in the presence of SC57101. YFLLRNP
alone did not cause any significant TXA2 generation in human
platelets. However, co-stimulation of platelets with 2MeSADP and
YFLLRNP in presence of SC57101 caused TXA2 generation,
indicating that the G12/13 pathways can rescue the inhibition
rendered by fibrinogen receptor antagonist. Hence, G12/13
pathways can substitute for integrin-mediated signaling by
probably activating similar effector molecules.
Role of c-Src and Syk downstream of integrin aIIbb3i n
thromboxane generation in platelets
Previous studies have shown that c-Src and Syk are signaling
effectors in platelets that are regulated by integrins [32]. In order
to identify the common signaling molecules downstream of
fibrinogen receptor and G12/13 pathways, we evaluated the role
of these individual kinases in ADP-induced TXA2 generation. We
reasoned that as these tyrosine kinases are activated downstream
of fibrinogen receptor and because ADP-induced thromboxane
generation requires signaling events from fibrinogen receptor, at
least one of these kinases could be crucial for ADP-induced
thromboxane generation. 2MeSADP-induced phosphorylation of
c-Src Y416 occurred in a time and concentration-dependent
manner (Figs. 2A and B). However, 2MeSADP-induced TXA2
generation in wild type mice was not different from the c-Src
knockout mice (Fig. 2C), suggesting that either other Src family
members may compensate for the absence of c-Src or that c-Src
activation downstream of ADP receptors is not involved in TXA2
generation. We then studied Syk kinase activation downstream of
ADP receptors. Syk kinase was not activated downstream of ADP
receptors (Fig. 2D), as determined by the phosphorylation of the
Tyr525/526 residues [33]. Taken together, these results suggest,
Figure 1. Regulation of thromboxane generation by G12/13
pathways. Non-aspirin-treated, washed human platelets were stimu-
lated with different concentrations of AYPGKF in presence and absence
of SC57101 (10 mM) (A) or other agonists (B) as indicated for 3.5 minutes
at 37uC under stirring conditions (900 rpm) in an aggregometer. After
3.5 minutes the reaction was stopped by snap- freezing in dry ice-
methanol bath. TXB2 levels were analyzed as described in ‘‘Materials
and Methods’’. The values are representative of 3 independent
experiments mean 6 S.E.M (n=3). The data were analyzed by student
t-test and ANOVA, ** P#0.005 was considered significant.
doi:10.1371/journal.pone.0016586.g001
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thromboxane generation in platelets.
Focal Adhesion Kinase is activated downstream of
integrins and G12/13 pathways
We next evaluated the activation of FAK by ADP receptors,
using Y397 phosphorylation as an activation marker. FAK
contains multiple tyrosine phosphorylation sites and the sequential
tyrosine phosphorylations of these sites causes complete FAK
activation beginning with autophosphorylation Y397 phosphory-
lation [34]. As shown in Figs. 3A & B, FAK is activated
downstream of ADP receptors and this activation is blocked by a
fibrinogen receptor antagonist but not by a pan SFK inhibitor
PP2. These results indicate FAK activation by ADP occurs in an
integrin-clustering-dependent manner, independent of SFKs.
We further investigated FAK activation downstream of G12/13
pathways. PAR agonists activate both Gq and G12/13 pathways in
platelets [11]. The Gq pathways can be inhibited by YM254890
[35] without affecting the Gi or G12/13 pathways [13]. Since
YFLLRNP is a weak, agonist for G12/13 pathways at low
concentrations and at higher concentrations can also activate Gq
pathways [16], we chose to stimulate platelets with AYPGKF
(500 mM) in the presence of YM254890 as tool for selective and
strong activation of G12/13 pathways for our phosphorylation
studies [13]. As shown in Fig. 3C, AYPGKF caused activation of
FAK in human platelets as determined by the phosphorylation of
Y397 residue. This phosphorylation was unaffected in the
presence of YM254890. It is important to note that 150 nM of
Figure 2. Role of c-Src and Syk downstream of integrin aIIbb3
in thromboxane generation in platelets. Aspirin–treated, washed
platelets were stimulated with 2MeSADP (100 nM) at various time
points (A) or with varying concentrations of 2MeSADP (B) for one
minute under stirring conditions at 37uC. The lysates were then
subjected to western blotting analysis and probed with anti-phospho-
(Y416) and total c-Src antibodies as lane loading control. Washed
murine (WT or c-Src KO) platelets, without aspirin-treatment, were
stimulated with 2MeSADP (100 nM) for 3.5 minutes and TXB2 levels
were analyzed (C) as described for Figure 1. The data are represented as
the % Fold increase over the control. Aspirin-treated washed platelets
were stimulated with 2MeSADP (100 nM) for (30–120 seconds) or
convulxin (100 ng/ml) for 30 seconds under stirring conditions at 37uC
(D). The lysates were then subjected to western blotting analysis and
probed with anti- phospho- Syk(Y 525/526) and total Syk antibodies as
lane loading control. The data are representative of at least 3 separate
experiments.
doi:10.1371/journal.pone.0016586.g002
Figure 3. Focal Adhesion Kinase is activated downstream of
integrins and G12/13 pathways. Aspirin treated, washed platelets
were stimulated with 2MeSADP (100 nM) in presence or absence of
reagents (as indicated) for 60 seconds under stirring conditions at 37uC
(A). The lysates were then subjected to western blotting analysis and
probed with anti- phospho- FAK (Y-397) and total FAK antibodies as
lane loading control. The data are representative of mean 6 S.E.M
(n=3). The data was analyzed by ANOVA and * P#0.05 was considered
significant (B). Aspirin-treated washed platelets were stimulated with
AYPGKF (500 mM) in presence or absence of YM254890 (150 nM) (C),
The lysates were then subjected to western blotting analysis and
probed with anti- phospho- FAK (Y-397) and total FAK antibodies as
lane loading control.
doi:10.1371/journal.pone.0016586.g003
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secretion [13] and hence autophosphorylation of FAK on Y397 is
through G12/13 pathways but not by outside-in signaling.
Signaling pathways regulating FAK activation
downstream of G12/13 pathways
We have shown that G12/13 pathways activated by AYPGKF in
the presence of YM254890 can activate FAK (Fig. 3A). Under these
conditions we used pharmacological inhibitors to evaluate the
signaling molecules that could regulate FAK phosphorylation. As
shown in Figs. 4A&B, PP2, a pan SFK inhibitor abolished FAK
phosphorylation mediated by G12/13 pathways. Our results from
Figs. 4C&D show that Rho kinase inhibitors H1152 and Y27632 also
markedly inhibited G12/13-mediated FAK phosphorylation. These
results indicate that both SFKs and Rho kinase play an important
role in FAK activation downstream of G12/13 pathways in platelets.
In order to further delineate the signaling pathways downstream of
G12/13, we also studied Src Y416 phosphorylation in presence of Rho
kinase inhibitors.As shown in Figs. 4E&F, G12/13-mediated Src Y416
phosphorylation was dramatically inhibited in presence of Rho kinase
inhibitors H1152 and Y27632, thus suggesting that SFKs are
activated downstream of Rho kinase in the G12/13 signaling cascade.
Evaluation of FAK as a common signaling effector
molecule regulating thromboxane generation
downstream of integrins and G12/13 pathways
We next evaluated whether activated FAK played a role in
ADP-induced TXA2 generation. TAE-226 has recently been
identified as a selective inhibitor of FAK with an IC50 of 5.5 nM
[36]. To determine the effect of FAK inhibition on ADP-induced
thromboxane generation platelets were treated with varying
concentrations of TAE-226. As demonstrated in Fig. 5A, TXA2
generation was significantly inhibited by TAE-226 at a higher
concentration of 2 mM. Pharmacological inhibitors are often
known to have off target and broad-spectrum effects. The
specificity of TAE-226 was never evaluated in platelets and
reports suggest that TAE-226 inhibits Pyk2 (a Focal Adhesion
kinase family member) with an IC50 of 5 nM [37]. Hence, we
studied thromboxane generation in WT and Pf4-Cre/FAK-floxed
mice platelets. Murine platelets from WT and Pf4-Cre/FAK-
floxed were stimulated with 100 nM of 2MeSADP and throm-
boxane levels were measured from WT and Pf4-Cre/FAK-floxed
mice samples. As shown in Fig. 5B there was no significant
difference observed thromboxane levels and aggregation tracings
(Fig. 5C) between WT and Pf4-Cre/FAK-floxed. These results
suggest that TAE-226 might exhibit some non-specific effects, and
FAK is not the common signaling molecule regulating thrombox-
ane generation downstream of integrins and G12/13 pathways.
Discussion
Activated platelets release positive feedback mediators such as
ADP and TXA2. The molecular mechanisms involved in
thromboxane generation by different platelet agonists are not
clearly understood. Weaker agonists such as ADP require outside-
in signaling through activated fibrinogen receptor to cause
thromboxane generation in platelets. Patients with Glanzmann’s
Figure 4. Signaling pathways regulating FAK activation downstream of G12/13 pathways. Aspirin-treated, washed human platelets were
pre-treated with different inhibitors (as indicated) for 5 minutes at 37uC followed by stimulation with AYPGKF (500 mM) for 90 seconds under stirring
conditions at 37uC in an aggregometer. The lysates were then subjected to western blotting analysis and probed with anti- phospho FAK (Y-397) and
total FAK antibodies as lane loading control (A &C) or anti- phospho- Src (416) and total c-Src antibodies as lane loading control (E). Quantitative data,
normalized to the lane loading control, are representative of mean 6 S.E.M (n=3). The data was analyzed by ANOVA and * P#0.05 was considered
significant (B, D, and F).
doi:10.1371/journal.pone.0016586.g004
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and G12/13 pathways. Non-aspirin-treated, washed human platelets were pre-treated with varying concentrations of TAE-226 for 5 minutes at 37uC
(A) and murine platelets from WT and Pf4-Cre/Fak-Floxed mice (B) were stimulated with 2MeSADP (100 nM) for 3.5 minutes and TXB2 levels were
analyzed as described for Figure 1. Aggregation tracings were measured from WT and Pf4-Cre/Fak-Floxed mice and representative tracings are shown
(C). The values are representative of 3 independent experiments mean 6 S.E.M (n=3). The data were analyzed by ANOVA and student t-test,
*P #0.05 was considered significant.
doi:10.1371/journal.pone.0016586.g005
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ADP but not with thrombin [38]. Our results show that PAR
agonists mediate TXA2 generation independent of the integrin
signaling. Previous studies by Stefanini et al [39] showed that
stimulation of platelets with high and low doses of GPVI agonist
convulxin in the presence of integrin blockers showed a marginal
decrease in thromboxane generation, indicating that thromboxane
generation downstream of GPVI receptors is not solely dependent
on integrins. Thus, these results indicate that platelets can generate
thromboxane in an integrin-dependent and-independent manner.
Since PAR receptors can activate G12/13 pathways we reasoned
that there might be a common signaling molecule, which could be
activated by both G12/13 pathways (which are not activated by
ADP) and integrins. This common signaling molecule might
regulate TXA2 generation downstream of G12/13 pathways
independent of integrins.
It has been known that several platelet agonists cause activation
of G12/13, but not much is known about the intracellular signaling
pathways downstream of this activation. Studies from our group
have shown that G12/13 pathways activate Src family kinases in
platelets [13]. Klages et al [12] showed that G12/13 proteins can
activate tyrosine kinases such as Syk and c-Src. Interestingly these
kinases are also known to be activated downstream of outside-in
signaling [32]. Although integrins and G12/13 pathways activate
c-Src, it is clear that this kinase has no significant role in
thromboxane generation downstream of ADP receptors (Fig. 2C).
Interestingly, thromboxane A2, an agonist that couples to Gq and
G12/13 [11], still caused the phosphorylation of p72Syk in Gq-
deficient mice [12]. This result suggests that activation of Syk
might occur downstream of G12/13 signaling. However, Syk does
not appear to be activated downstream of ADP receptors (Fig. 2D).
Hence, both c-Src and Syk can be ruled out as the common
signaling molecule mediating thromboxane generation down-
stream of G12/13 and integrin pathways.
Our studies show that FAK is differentially activated down-
stream integrins (Figs. 3A and B) and G12/13 pathways (Figs. 3C,
4A and B). However, recently it was reported by Gong et al [40]
that G13 binds to integrin aIIbb3 and mediates outside-in
signaling. Gong et al claim that Rho activation downstream of
PARs and integrins is temporally and spatially regulated and
mediates opposing effects. With regards to FAK activation in
platelets it does not seem to be the probable mechanism since
ADP-induced FAK activation is independent of SFKs (Figs. 3A
and B) and downstream of G12/13 pathways FAK activation is
SFK and Rho-dependent (Figs. 4A and 4C). Thus, there maybe
some other integrin-mediated signaling pathways regulating FAK
activation in platelets. Upstream of FAK, SFKs are activated by
G12/13 pathways [13]. SFKs regulate FAK activation downstream
of G12/13 pathways but not downstream of integrin signaling
(Figs. 4A and 3A). Although integrin signaling leads to c-Src and
FAK activation, our results suggest that Src/Syk pathways and
FAK pathways are independently activated by integrins as
outlined in Fig. 6, with possible differential functional implications
in platelets.
G12/13 pathways are known to activate RhoA/Rho kinase
pathways leading to calcium-independent shape change [12,14].
These pathways are also known to regulate dense granule release
through RhoA/Rho kinase pathways [15]. Our studies show that
Rho kinase pathways regulate FAK activation through SFKs
(Figs. 4E&F). This is a novel observation and indicates that Rho
kinase pathways are the nodal point of SFK activation, ppIMd
phosphatase, and other pathways regulating dense granule release.
We postulate that these pathways are independent of each other
as; inhibition of SFKs (with PP2) has no significant effect on PAR-
mediated shape change or dense granule release in aspirin-treated
platelets [41]. Hence, SFK activation occurs downstream, rather
than upstream, of RhoA/Rho kinase pathways upon G12/13
stimulation as outlined in Fig. 6. If SFK activation were to occur
upstream of Rho kinase pathways, then SFK inhibition would
have affected platelet shape change as well as dense granule release
reaction in aspirin-treated platelets.
Furthermore, complementary approaches e.g. pharmacological
FAK inhibitor TAE-226 and Pf4-Cre/Fak-Floxed mice were
employed to evaluate role of FAK in thromboxane generation.
Pre-treatment of platelets with various doses of TAE-226 did not
lead to significant decrease in thromboxane levels. However,
inhibition of thromboxane generation was observed at 2 mM
concentration only (Fig. 5A). Similarly thromboxane generation
was not affected in Pf4-Cre/Fak-Floxed mice, when compared to
WT littermates (Fig. 5B). These results indicate that FAK does not
contribute to thromboxane generation downstream of integrins
and TAE-226 might have some non-specific effects on platelets.
Since our data indicates that loss of FAK does not translate into
diminished thromboxane generation, it is possible that some other
tyrosine kinases might be compensating for the loss of FAK in
platelets, however it might be unlikely since previous studies in
Pf4-Cre/Fak-Floxed mice showed differences in tail bleeding times
and platelet spreading and no upregulation of Pyk2 expression was
observed in FAK-Floxed mice [23]. Recently, another FAK
inhibitor PF-573,228 was shown to inhibit platelet aggregation
[42]. However, our platelet aggregation studies comparing WT
and Pf4-Cre/FAK-Floxed mice did not show any differences in
aggregation (Fig. 5C). Furthermore, as our previous studies have
shown that ERK can be activated even in the presence of integrin
antagonists [43] therefore, ERK cannot be the common effector
downstream of integrins and G12/13 pathways.
Thus, we conclude that G12/13 pathways through a Rho kinase/
SFK dependent manner activate FAK. However, FAK activation
downstream of integrins occurs independently of SFKs. Finally
none of the three-tyrosine kinases c-Src, Syk or FAK seems to play
a role in thromboxane generation downstream of integrins. Thus,
the common signaling effector, possibly a tyrosine kinase,
contributing to thromboxane downstream of G12/13 pathways
and integrins remains yet to be identified.
Ethical Statement
Approval for this study was obtained from the Institutional
Review Board of Temple University (Philadelphia, PA), and mice
were used for physiological measurements using the protocol ID
number 3364, approved by the Institutional Animal Care and Use
Committee (IACUC).
Materials and Methods
Materials
2MeSADP, Apyrase grade VII, human fibrinogen, acetylsa-
licylic acid, were obtained from Sigma (St. Louis, MO). SC57101
was gift from Searle Research and Development (Skokie, IL).
Hexapeptide AYPGKF was custom synthesized at Invitrogen
(Carlsbad, CA). Convulxin was purchased from Centerchem Inc.
(Norwalk, CT). The heptapeptide, YFLLRNP was synthesized by
New England Biolabs (Beverly, MA) or by Research Genetics
(Huntsville, AL). Phospho-specific antibodies against Y416 Src
family, anti-Syk Y525/526, Total Src and Total Syk were
obtained from Cell Signaling Technologies (Beverly, MA).
Antibodies against FAK Y397 were obtained from Millipore,
(Bedford, MA) and Total FAK was from Biosource (Camarillo,
USA). PP2 and PP3 were purchased from Biomol (Plymouth
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Toronto Research Chemicals (North York, ON). Y-27632 was
obtained from Calbiochem (San Diego, CA). YM-254890 was a
gift from Yamanouchi Pharmaceuticals Co., Ltd (Ibaraki, Japan).
TAE-226 was generously provided by (Novartis Pharma AG,
Switzerland). The other reagents were of reagent grade, and de-
ionized water was used throughout.
Animals
8–12 weeks old Pf4-Cre, and Pf4-Cre/FAK-floxed mice were
generated in accordance with previously described protocol [44].
The generation of Src KO mice was described previously [45] and
these mice along with wild type littermates in C57BL/6
background were used in the experiments.
Preparation of washed human and murine platelets
All experiments with human volunteers were performed in
accordance with Declaration of Helsinki. Whole blood was drawn
from healthy, human volunteers selected from students, staff or workers
at the Temple University with written informed consent. Donated
blood was collected in tubes containing one-sixth volume of acid citrate
dextrose (ACD) (2.5 g of sodium citrate, 1.5 g of citric acid, and 2 g of
glucose in 100 ml of de-ionized water). Citrated blood was centrifuged
and platelets were isolated with previously established protocol [46].
Isolation of mouse platelets
Blood was collected from the vena cava of anaesthetized mice
into syringes containing one-tenth blood volume of 3.8% sodium
citrate as anticoagulant. Red blood cells were removed by
centrifugation at 1006 g for 10 min. PRP was recovered, and
platelets were pelleted at 4006 g for 10 min. The platelet pellet
was resuspended in Tyrode’s buffer (pH 7.4) containing 0.01 unit/
ml apyrase. The isolated platelets were subsequently used for
experiments.
Western blot analysis
Aliquots of aspirin-treated, washed human platelets were lysed
using Laemmli buffer in presence of dithiothreitol (DTT)
(100 mM) and boiled for 10 min. The platelet lysates were loaded
onto a 10% -Tris-glycine gel, subjected to SDS-PAGE (Sodium
Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis), and
transferred to PVDF membrane. Nonspecific binding sites were
blocked by incubating the membrane in Tris–buffered saline-
Tween (TBST; 20 mM Tris, 140 mM NaCl, 0.1% (vol/vol)
Tween 20) containing 3% (wt/vol) bovine serum albumin (BSA)
and 5% (vol/vol) Irish cream for 30 min at RT, followed by
incubating it overnight at 4uC with gentle agitation in the primary
antibody (1:1000 dilution for anti-FAK Y397, anti-Src Y416, anti-
Syk Y525/526, anti-Syk, Anti-FAK and anti-Src in TBST with
Figure 6. Model depicting the regulation of TXA2 generation by G12/13 pathways and integrins through FAK. Integrin clustering leads
to FAK activation (1). Fibrinogen receptor antagonist SC57101 prevents integrin clustering hence inhibits FAK activation (2). FAK can be activated in
an integrin-independent manner by G12/13 pathways (3). FAK is activated downstream of Rho kinase and SFKs upon stimulation of G12/13 pathways
(4). FAK can be inhibited by TAE-226 (5). Common effector molecule downstream of integrins and G12/13 pathways contributing to thromboxane
generation are unknown (6).
doi:10.1371/journal.pone.0016586.g006
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with an alkaline phosphatase-labeled secondary antibody (1:5000
dilutions in TBST with 3% BSA) for 1 hour at RT. After
additional washing steps, membranes were incubated with
chlordiazepoxide (CDP)–StarH chemiluminescent substrate (Tro-
pix, Bedford, MA) for 10 min at RT, and immunoreactivity was
detected using a Fuji Film Luminescent Image Analyzer (LAS-
3000 CH; Tokyo, Japan).
Measurement of TXA2 generation in human and mice
platelets
Washed human platelets (500 ml brought to a concentration of
2610
8 platelets/mL) were stimulated with 2MeSADP (100 nM) in
a lumi-aggregometer at 37uC with stirring at 900 rpm, in the
presence or absence of TAE-226. Similarly murine platelets from
WT and Pf4-Cre/FAK-floxed mice (250 ml brought to a
concentration of 2610
8 platelets/mL) were stimulated with
2MeSADP (100 nM). After 3.5 min of stimulation, the reaction
was stopped by quickly freezing the sample in a dry ice-methanol
bath. The level of TXB2, the stable metabolite of TXA2 was
measured using a previously established protocol [47].
Statistical Analysis
The results were quantified, expressed as mean 6 S.E.M. The
data was statistically analyzed using Student’s t-test and ANOVA.
*P#0.05/ ** P#0.05 were considered significant.
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